

DESCRIPTION

Source Human embryonic kidney cell, HEK293-derived human IL-21 protein
Gln32-Ser162
Accession # Q9HBE4.3

N-terminal Sequence Analysis Blocked at Gln32, revealing Asp33 after deblocking

Predicted Molecular Mass 15 kDa

SPECIFICATIONS

SDS-PAGE 15-17 kDa, under reducing conditions.

Activity Measured in a cell proliferation assay using B9 mouse hybridoma cells.
The ED₅₀ for this effect is 3.00-30.0 ng/mL.

Endotoxin Level <0.10 EU per 1 µg of the protein by the LAL method.

Purity >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Formulation Lyophilized from a 0.2 µm filtered solution in PBS with Trehalose. See Certificate of Analysis for details.

PREPARATION AND STORAGE

Reconstitution Reconstitute 10 µg size at 100 µg/mL and other sizes at 500 µg/mL in PBS.


Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 3 months, -20 to -70 °C under sterile conditions after reconstitution.


DATA

Bioactivity



Recombinant Human IL-21 (HEK293 Expressed) Protein Bioactivity. Recombinant Human IL-21 stimulates B9 mouse hybridoma cell proliferation. The ED₅₀ for this effect is 3.00-30.0 ng/mL.

SDS-PAGE



Recombinant Human IL-21 (HEK293 Expressed) Protein SDS-PAGE. 2 µg/lane of Recombinant Human IL-21 (HEK293 Expressed) Protein (Catalog # 11393-IL) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 15-17 kDa, under reducing conditions.

BACKGROUND

IL-21 (Interleukin-21) is a potent cytokine regulating many cell types of the immune system. IL-21 is produced by activated T follicular helper cells (Tfh), Th17 cells, and NKT cells (2-6). Tfh-derived IL-21 plays an important role in the development of humoral immunity through its autocrine effects on the Tfh cell and paracrine effects on immunoglobulin affinity maturation, plasma cell differentiation, and B cell memory responses (4, 8, 9). IL-21 protein regulates several aspects of T cell function. It co-stimulates the activation, proliferation, and survival of CD8+ T cells and NKT cells and promotes Th17 cell polarization (3, 5, 6, 11, 12). IL-21 blocks the generation of regulatory T cells and their suppressive effects on CD4+ T cells (13, 14). In addition to its role in T cell biology, IL-21 also plays a critical role in B cell activation, proliferation, differentiation, and apoptosis (2). It is also required for the migration of dendritic cells to draining lymph nodes (10). And IL-21 suppresses cutaneous hypersensitivity reactions by limiting allergen-specific IgE production and mast cell degranulation (16). In the autoimmune disease Systemic lupus erythematosus (SLE), a link between IL-21 and SLE disease susceptibility and progression was recently reported (19). IL-21 protein exerts its biological effects through a heterodimeric receptor complex of gamma c and the IL-21-specific IL-21 R (2, 7). IL-21 is an approximately 14 kDa four-helix-bundle member of the family of cytokines that utilize the common gamma chain (gamma c) as a receptor subunit. gamma c is also a subunit of the receptors for IL-2, IL-4, IL-7, IL-9, and IL-15 (1). IL-21 R engagement enhances the cytolytic activity and IFN-gamma production of activated NK cells but limits the expansion of resting NK cells (15). Dysregulation of the IL-21/IL-21 R system contributes to the development of multiple immunological disorders (1, 17). The 133 amino acid (aa) mature human IL-21 protein shares 63% and 61% aa sequence identity with mouse and rat IL-21 protein, respectively. Alternative splicing generates an additional isoform with a substitution of the C-terminal 16 amino acids (18).

References:

1. Tangye, S.G. (2015) *Curr. Opin. Immunol.* **34**:107.
2. Parrish-Novak, *et al.* (2000) *Nature* **408**:57.
3. Coquet, J.M. *et al.* (2007) *J. Immunol.* **178**:2827.
4. Vogelzang, A. *et al.* (2008) *Immunity* **29**:127.
5. Korn, T. *et al.* (2007) *Nature* **448**:484.
6. Nurieva, R. *et al.* (2007) *Nature* **448**:480.
7. Asao, H. *et al.* (2001) *J. Immunol.* **167**:1.
8. Zotos, D. *et al.* (2010) *J. Exp. Med.* **207**:365.
9. Rankin, A.L. *et al.* (2011) *J. Immunol.* **186**:667.
10. Jin, H. *et al.* (2009) *J. Clin. Invest.* **119**:47.
11. Frohlich, A. *et al.* (2009) *Science* **324**:1576.
12. Yi, J.S. *et al.* (2009) *Science* **324**:1572.
13. Peluso, I. *et al.* (2007) *J. Immunol.* **178**:732.
14. Bucher, C. *et al.* (2009) *Blood* **114**:5375.
15. Kasaian, M.T. *et al.* (2002) *Immunity* **16**:559.
16. Tamagawa-Mineoka, R. *et al.* (2011) *J. Invest. Dermatol.* **131**:1513.
17. Ma, J. *et al.* (2011) *Cytokine* **56**:133.
18. Rahman, M. *et al.* (2007) *FEBS Lett.* **581**:4001.
19. Wang, *et al.* (2018) *Nature Commun.* **9**: 1758.